[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):75-78. doi: 10.3760/cma.j.issn.0253-2727.2023.01.015.

[Article in Chinese]

Authors

J Lu¹, H Y He¹, L Li¹, W T Qiang¹, J Liu¹, P Guo¹, H Jiang¹, W J Fu¹, J Du¹

Affiliation

¹ Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.

PMID: 36987729
PMCID: PMC10067371
DOI: 10.3760/cma.j.issn.0253-2727.2023.01.015

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Thalidomide / therapeutic use

Substances

pomalidomide
Thalidomide
Dexamethasone